Dr. Deepa Manwani, M.D.
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
TN license 74242 · NY license 209287
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $2,968 in total to this clinician.
| Pfizer Inc. | $2,400 |
|---|---|
| Novartis Pharma AG | $330 |
| Novo Nordisk Inc | $125 |
| Terumo Bct, Inc. | $114 |
| Consulting Fee | $2,400 |
|---|---|
| Travel and Lodging | $330 |
| Food and Beverage | $238 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. May 19, 2025 | Consulting Fee | $2,400 |
| Novartis Pharma AG Dec 9, 2025 | Travel and Lodging ADAKVEO · Hematology · travel to New Orleans, LA | $330 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $25,184 in research payments for these studies, mostly to the institutions running them.
- A phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or without Hydroxyurea Hydroxycarbamide in Sequential Descending Age Groups of Pediatric Sickle Cell Dis…
Novartis Pharmaceuticals Corporation - A phase II Multicenter Study to Confirm PK PD of crizanlizumab with or without Hydroxyurea Hydroxycarbamide in Adult Sickle Cell Disease Patients with history of VOC
Novartis Pharmaceuticals Corporation - A randomized open label multicenter two arm phase II study to evaluate treatment compliance efficacy and safety of an improved deferasirox formulation granules in pediatric patients with iron overload
Novartis Pharmaceuticals Corporation - A phase 23 randomized multicenter study of GBT021601 administered orally to participants with sickle cell disease and an openlabel pharmacokinetics study in pediatric participants with sickle cell disease
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.